Table 2: Univariate association between patients characteristics and 6-month HF death in non-diabetic and diabetic decompensated HF patients.

Non-diabetics
HF death   
HR (95% CI)
p valueDiabetics
HF death   
HR (95% CI)
p value

Clinical characteristics
 Age (per year)1.02 (1.00–1.05)0.081.02 (0.98–1.05)0.36
 Male sex1.38 (0.77–2.48)0.281.36 (0.75–2.45)0.31
 Ischemic aetiology of HF1.04 (0.56–1.91)0.901.10 (0.61–1.98)0.76
 Arterial hypertension history0.62 (0.34–1.13)0.120.47 (0.23–0.96)0.04
 Atrial fibrillation history2.10 (1.14–3.89)0.022.03 (1.11–3.72)0.02
 LVSD versus HFpEF1.58 (0.86–2.91)0.141.25 (0.68–2.33)0.47
 NYHA class at admission (IV versus others)1.19 (0.68–2.17)0.561.20 (0.64–2.26)0.57
 SBP at admission <115 mmHg3.16 (1.76–5.67)<0.0011.58 (0.84–2.98)0.16
 BMI at admission (per Kg/m2)0.94 (0.87–1.01)0.080.97 (0.90–1.05)0.45
Laboratory at discharge
 Anaemia2.37 (1.20–4.69)0.011.81 (0.91–3.58)0.09
 Renal dysfunction1.39 (0.75–2.56)0.301.54 (0.85–2.80)0.16
 Hyponatremia1.17 (0.60–2.27)0.651.76 (0.94–3.29)0.08
 Total cholesterol <125 mg/dL1.79 (0.88–3.62)0.101.98 (1.04–3.80)0.04
 C-reactive protein (per mg/L)1.00 (0.99–1.01)0.901.00 (0.99–1.01)0.80
 BNP (per 100 pg/mL)1.02 (1.01–1.03)<0.0011.02 (1.01–1.03)<0.001
 Glycosylated haemoglobin (per %)0.74 (0.36–1.52)0.421.04 (0.85–1.26)0.72
Discharge medication
 Beta-blocker0.85 (0.44–1.61)0.610.41 (0.22–0.76)0.004
 ACEi or ARB0.35 (0.20–0.64)0.0010.41 (0.21–0.78)0.002
 Spironolactone0.75 (0.37–1.51)0.420.86 (0.40–1.85)0.70
 Statin0.62 (0.34–1.13)0.120.98 (0.51–1.88)0.94
 Antiplatelet drugs1.22 (0.66–2.26)0.520.98 (0.49–1.94)0.95

ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor 1 blocker, BMI: body mass index; BNP: B-type natriuretic peptide; CI: confidence interval; HF: heart failure; HFpEF: Heart failure with preserved ejection fraction; HR: hazard ratio; LVSD: left ventricular systolic dysfunction; NYHA: New York Heart Association; SBP: systolic blood pressure.